# Trially

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/trially

- Industry: Software
- Headquarters: Kansas City, US
- Website: www.trially.ai
- Total disclosed funding: $4.8M
- Latest round: Seed (Aug 8, 2025)
- Investors on record: 8

## About

Trially Inc. is an innovative company specializing in artificial intelligence solutions for enhancing patient recruitment in clinical trials, notably through its proprietary platform, Trially®, which leverages advanced technology to optimize patient enrollment processes. Trially Inc., founded in 2023, is based in Kansas City, US. The company focuses on developing artificial intelligence tools intended to streamline patient recruitment for clinical trials. In August 2025, Trially Inc. raised USD 4.7 million in seed funding led by new investor Flyover Capital, with participation from other new investors Alpaca, Atria Ventures, Blu Venture Investors, Looking Glass Capital, Redbud VC, The Council, and Gaingels. The founder's background includes previous ventures in technology and healthcare, driving the mission of improving clinical trial processes.Trially AI offers a comprehensive HIPAA-compliant clinical trial platform aimed at enhancing patient recruitment for clinical studies. The core product, Trially®, employs advanced AI and machine learning to analyze unstructured Electronic Health Record (EHR) data, allowing life science leaders to efficiently identify and enroll qualified patients. Features include a user-friendly drag-and-drop interface for protocol matching, real-time visibility of patient candidates, and analytics that guide recruitment strategies. Trially serves a diverse clientele, including sponsors, contract research organizations (CROs), and clinical research sites, primarily in the pharmaceutical and biotechnology sectors across North America and Europe.Trially operates on a subscription-based revenue model, where clients pay for access to its clinical trial recruitment platform. Agreements generally involve annual subscriptions or usage-based fees tailored to specific client needs. While precise pricing details are not disclosed, the platform aims to enhance client efficiency in identifying patient candidates and managing recruitment processes. The flagship Trially® platform is designed to optimize patient recruitment for complex studies, highlighting the potential return on investment for clients through improved enrollment rates and reduced costs associated with traditional recruitment methods.Trially Inc. is focused on expanding its product offerings and entering new markets. The company is currently developing additional features for its platform, with anticipated releases aimed at further improving patient recruitment strategies. Additionally, it plans to expand its presence in Europe and other international markets by the end of 2026. The company will use the August 2025 funding to support the adoption of its platform across research sites.

## Funding rounds

- Seed, Aug 8, 2025, $4.8M — Blu Venture Investors, Alpaca, Flyover Capital, Gaingels, Looking Glass Capital, The Council, Atria Ventures, Redbud VC

## Investors

- Blu Venture Investors (https://capitalatlas.ai/funds/blu-venture-investors) — Seed
- Alpaca (https://capitalatlas.ai/funds/alpaca) — Seed
- Flyover Capital (https://capitalatlas.ai/funds/flyover-capital) — Seed
- Gaingels (https://capitalatlas.ai/funds/gaingels) — Seed
- Looking Glass Capital (https://capitalatlas.ai/funds/looking-glass-capital) — Seed
- The Council (https://capitalatlas.ai/funds/the-council) — Seed
- Atria Ventures (https://capitalatlas.ai/funds/atria-ventures) — Seed
- Redbud VC (https://capitalatlas.ai/funds/redbud-vc) — Seed